Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study

Andrew M. Tershakovec; William F. Keane; Zhongxin Zhang; Paulette A. Lyle; Gerald B. Appel; Janet B. McGill; Hans Henrik Parving; Mark E. Cooper; Shahnaz Shahinfar; Barry M. Brenner

doi:10.2337/dc07-0196

Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study

Andrew M. Tershakovec, William F. Keane, Zhongxin Zhang, Paulette A. Lyle, Gerald B. Appel, Janet B. McGill, Hans Henrik Parving, Mark E. Cooper, Shahnaz Shahinfar, Barry M. Brenner

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/ proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between LDL cholesterol levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebobased antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.

Original language	English
Pages (from-to)	445-447
Number of pages	3
Journal	Diabetes care
Volume	31
Issue number	3
DOIs	https://doi.org/10.2337/dc07-0196
State	Published - Mar 2008

Access to Document

10.2337/dc07-0196

Cite this

@article{c1b4455eda2148f98608d9c3cbffa322,

title = "Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study",

abstract = "Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/ proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between LDL cholesterol levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebobased antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.",

author = "Tershakovec, {Andrew M.} and Keane, {William F.} and Zhongxin Zhang and Lyle, {Paulette A.} and Appel, {Gerald B.} and McGill, {Janet B.} and Parving, {Hans Henrik} and Cooper, {Mark E.} and Shahnaz Shahinfar and Brenner, {Barry M.}",

year = "2008",

month = mar,

doi = "10.2337/dc07-0196",

language = "English",

volume = "31",

pages = "445--447",

journal = "Diabetes care",

issn = "0149-5992",

number = "3",

}

TY - JOUR

T1 - Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study

AU - Tershakovec, Andrew M.

AU - Keane, William F.

AU - Zhang, Zhongxin

AU - Lyle, Paulette A.

AU - Appel, Gerald B.

AU - McGill, Janet B.

AU - Parving, Hans Henrik

AU - Cooper, Mark E.

AU - Shahinfar, Shahnaz

AU - Brenner, Barry M.

PY - 2008/3

Y1 - 2008/3

N2 - Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/ proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between LDL cholesterol levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebobased antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.

AB - Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/ proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between LDL cholesterol levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebobased antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.

UR - http://www.scopus.com/inward/record.url?scp=44449173148&partnerID=8YFLogxK

U2 - 10.2337/dc07-0196

DO - 10.2337/dc07-0196

M3 - Article

C2 - 18070995

AN - SCOPUS:44449173148

SN - 0149-5992

VL - 31

SP - 445

EP - 447

JO - Diabetes care

JF - Diabetes care

IS - 3

ER -

Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this